These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 8492955)
21. Myopathy in HIV infection: the role of zidovudine and the significance of tubuloreticular inclusions. Lane RJ; McLean KA; Moss J; Woodrow DF Neuropathol Appl Neurobiol; 1993 Oct; 19(5):406-13. PubMed ID: 8278024 [TBL] [Abstract][Full Text] [Related]
22. Peripheral nerve function in persons with asymptomatic or minimally symptomatic HIV disease: absence of zidovudine neurotoxicity. Bozzette SA; Santangelo J; Villasana D; Fraser A; Wright B; Jacobsen C; Hayden E; Schnack J; Spector SA; Richman DD J Acquir Immune Defic Syndr (1988); 1991; 4(9):851-5. PubMed ID: 1654410 [TBL] [Abstract][Full Text] [Related]
24. Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection. Chen SC; Barker SM; Mitchell DH; Stevens SM; O'Neill P; Cunningham AL Pathology; 1992 Apr; 24(2):109-11. PubMed ID: 1641255 [TBL] [Abstract][Full Text] [Related]
25. Didanosine therapy in patients intolerant of or failing zidovudine therapy. Rathbun RC; Martin ES Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093 [TBL] [Abstract][Full Text] [Related]
26. AZT myopathy and HIV-1 polymyositis: one disease or two? Walsh K; Kaye K; Demaerschalk B; Stewart S; Crukley J; Hammond R Can J Neurol Sci; 2002 Nov; 29(4):390-3. PubMed ID: 12463497 [TBL] [Abstract][Full Text] [Related]
27. High incidence of zidovudine induced anaemia in HIV infected patients in eastern India. Agarwal D; Chakravarty J; Chaube L; Rai M; Agrawal NR; Sundar S Indian J Med Res; 2010 Oct; 132():386-9. PubMed ID: 20966515 [TBL] [Abstract][Full Text] [Related]
28. Zidovudine--the first year of experience. Williams I; Gabriel G; Cohen H; Williams P; Tedder RS; Machin S; Weller IV J Infect; 1989 Jan; 18 Suppl 1():23-31. PubMed ID: 2915140 [No Abstract] [Full Text] [Related]
29. [Muscular complications in HIV infection]. Authier FJ; Chariot P; Gherardi R Arch Anat Cytol Pathol; 1997; 45(2-3):174-8. PubMed ID: 9382610 [TBL] [Abstract][Full Text] [Related]
34. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Mhiri C; Baudrimont M; Bonne G; Geny C; Degoul F; Marsac C; Roullet E; Gherardi R Ann Neurol; 1991 Jun; 29(6):606-14. PubMed ID: 1892364 [TBL] [Abstract][Full Text] [Related]
35. Early features of zidovudine-associated myopathy: histopathological findings and clinical correlations. Cupler EJ; Danon MJ; Jay C; Hench K; Ropka M; Dalakas MC Acta Neuropathol; 1995; 90(1):1-6. PubMed ID: 7572071 [TBL] [Abstract][Full Text] [Related]
36. Myopathy in human immunodeficiency virus-infected children receiving long-term zidovudine therapy. Walter EB; Drucker RP; McKinney RE; Wilfert CM J Pediatr; 1991 Jul; 119(1 Pt 1):152-5. PubMed ID: 1906098 [No Abstract] [Full Text] [Related]
37. Human immunodeficiency virus wasting syndrome may represent a treatable myopathy. Simpson DM; Bender AN; Farraye J; Mendelson SG; Wolfe DE Neurology; 1990 Mar; 40(3 Pt 1):535-8. PubMed ID: 2314598 [TBL] [Abstract][Full Text] [Related]
38. Zidovudine and other drugs against HIV. Drug Ther Bull; 1988 Dec; 26(26):101-4. PubMed ID: 3065024 [No Abstract] [Full Text] [Related]